AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7668039 — intervention group
Group type: EXPERIMENTAL
Intervention: WC/rBS cholera vaccine
Number of subjects: 541
Study 7668039 — intervention group
Group type: COMPARATOR
Intervention: Escherichia coli K12 placebo
Number of subjects: 541
Study 8267992 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium chloride (50 mmol)
Number of subjects: 130
Study 8267992 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 130
Study 4055163 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol + l‐methionine (5:1)
Number of subjects: 10
Study 4055163 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (1,500 mg)
Number of subjects: 10
Study 31376419 — intervention group
Group type: EXPERIMENTAL
Intervention: CRISPR/dCas9 system to label genomic loci
Number of subjects: 0
Study 31376419 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution wide-field imaging
Number of subjects: 0
Study 29549417 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (individuals who attended screening)
Number of subjects: 139075
Study 29549417 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (individuals diagnosed with diabetes)
Number of subjects: 139075
Study 29549417 — intervention group
Group type: COMPARATOR
Intervention: No-screening group (unscreened individuals diagnosed with diabetes)
Number of subjects: 139075
Study 27513414 — intervention group
Group type: EXPERIMENTAL
Intervention: Back school program applied over 2 weeks
Number of subjects: 40
Study 27513414 — intervention group
Group type: COMPARATOR
Intervention: Booklet for home use (Control)
Number of subjects: 40
Study 24655552 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HRT (1mg 17β‐estradiol and 0.5mg norethisterone acetate for 6 months)
Number of subjects: 76
Study 24655552 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal HRT (50μg/day estradiol alone for days 1-14 and 50μg/day estradiol plus 0.25mg/day norethisterone acetate for days 15-28 for 6 months)
Number of subjects: 76
Study 24655552 — intervention group
Group type: COMPARATOR
Intervention: Oral HRT
Number of subjects: 76
Study 24655552 — intervention group
Group type: COMPARATOR
Intervention: Transdermal HRT
Number of subjects: 76
Study 24655552 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral and transdermal HRT
Number of subjects: 76
Study 22295815 — intervention group
Group type: EXPERIMENTAL
Intervention: ST 9 plus SGB group
Number of subjects: 120
Study 22295815 — intervention group
Group type: EXPERIMENTAL
Intervention: ST 9 group
Number of subjects: 120
Study 22295815 — intervention group
Group type: COMPARATOR
Intervention: Common acupuncture group
Number of subjects: 120
Study 19657689 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month subcutaneous denosumab injection (60 mg) plus weekly oral placebo
Number of subjects: 1693
Study 19657689 — intervention group
Group type: COMPARATOR
Intervention: Weekly alendronate tablet (70 mg) plus 6-month subcutaneous placebo injection
Number of subjects: 1693
Study 18696021 — intervention group
Group type: EXPERIMENTAL
Intervention: s1 (initial slope of the VCO2/VO2-curve)
Number of subjects: 103
Study 18696021 — intervention group
Group type: EXPERIMENTAL
Intervention: peak VO2
Number of subjects: 103
Study 18696021 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP serum-levels
Number of subjects: 103
Study 18696021 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA-class
Number of subjects: 103
Study 18696021 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF
Number of subjects: 103
Study 18696021 — intervention group
Group type: EXPERIMENTAL
Intervention: combined endpoint of cardiovascular death and rehospitalization due to HF
Number of subjects: 103
Study 16195026 — intervention group
Group type: EXPERIMENTAL
Intervention: Pose method of running (12 weeks of instruction)
Number of subjects: 16
Study 16195026 — intervention group
Group type: COMPARATOR
Intervention: Usual running technique (control group)
Number of subjects: 16
Study 11812401 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 100
Study 11812401 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 100
Study 10518294 — intervention group
Group type: EXPERIMENTAL
Intervention: Re‐Flex Vertical Shock Pylon (VSP) prosthesis
Number of subjects: 5
Study 10518294 — intervention group
Group type: COMPARATOR
Intervention: Flex‐Foot (FF) prosthesis
Number of subjects: 5
Study 10518294 — intervention group
Group type: COMPARATOR
Intervention: Solid Ankle Cushion Heel (SACH) foot
Number of subjects: 5
Study 7547154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medication counselling for 3 months
Number of subjects: 0
Study 7547154 — intervention group
Group type: COMPARATOR
Intervention: No counselling
Number of subjects: 0
Study 2343272 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish applications every 3 months
Number of subjects: 254
Study 2343272 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish applications every 6 months
Number of subjects: 254
Study 2343272 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish applications every 3 months (high baseline DMFS)
Number of subjects: 254
Study 2343272 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish applications every 6 months (high baseline DMFS)
Number of subjects: 254
Study 35296 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 12
Study 35296 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 12
Study 35296 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (10 mg)
Number of subjects: 12
Study 35296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31806533 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (VR)
Number of subjects: 171
Study 31806533 — intervention group
Group type: EXPERIMENTAL
Intervention: Video
Number of subjects: 171
Study 31806533 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic pamphlet (e-pamphlet)
Number of subjects: 171
Study 31806533 — intervention group
Group type: COMPARATOR
Intervention: Vaccine Information Statements (VIS) only
Number of subjects: 171
Study 31207115 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase‐1 (HYAL‐1) expression measured by RT‐PCR in tumour tissues
Number of subjects: 50
Study 31207115 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva HA levels measured by ELISA method
Number of subjects: 50
Study 31207115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour tissue HA levels
Number of subjects: 50
Study 28163006 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of healthier products and promotional signs on snack vending machines
Number of subjects: 56
Study 28163006 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthier product guidelines on beverage machines
Number of subjects: 56
Study 28163006 — intervention group
Group type: EXPERIMENTAL
Intervention: Price reductions for healthier items
Number of subjects: 56
Study 28163006 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-way interaction of availability, price reduction, and promotional signs
Number of subjects: 56
Study 28163006 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall shift to healthier purchasing
Number of subjects: 56
Study 25854020 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated therapy of acupuncture and pingganjianpi decoction
Number of subjects: 47
Study 25854020 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol tablets (0.05 mg/kg per day, twice a day for 30 days)
Number of subjects: 47
Study 23986021 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical incision technique
Number of subjects: 163
Study 23986021 — intervention group
Group type: COMPARATOR
Intervention: Horizontal incision technique
Number of subjects: 163
Study 21371167 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal 0.5% bupivacaine 0.2-0.4 mg·kg(‐1) and intravenous 2 ml saline (Group B)
Number of subjects: 59
Study 21371167 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 0.5% bupivacaine 0.2-0.4 mg·kg(‐1) plus 1 μg·kg(‐1) clonidine and intravenous 2 ml saline (Group BCit)
Number of subjects: 59
Study 21371167 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 0.2-0.4 mg·kg(‐1) and intravenous 1 μg·kg(‐1) clonidine in 2 ml of saline (Group BCiv)
Number of subjects: 59
Study 18855032 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (1)H and (31)P MR spectroscopic imaging (MRSI)
Number of subjects: 14
Study 18855032 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 14
Study 17619660 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive digital images of drug products and online quizzes
Number of subjects: 0
Study 15049877 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11673035 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg
Number of subjects: 12
Study 11673035 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin 200 mg
Number of subjects: 12
Study 11673035 — intervention group
Group type: COMPARATOR
Intervention: Gemifloxacin
Number of subjects: 12
Study 9626153 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 IU/day recombinant human growth hormone (rhGH)
Number of subjects: 47
Study 9626153 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 IU/day recombinant human growth hormone (rhGH)
Number of subjects: 47
Study 9626153 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 IU/day recombinant human growth hormone (rhGH)
Number of subjects: 47
Study 7897380 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A (720 ELISA units) and hepatitis B (20 micrograms) vaccine
Number of subjects: 150
Study 7897380 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed administration of hepatitis A and hepatitis B vaccines
Number of subjects: 150
Study 7897380 — intervention group
Group type: COMPARATOR
Intervention: Separate administration of hepatitis A and hepatitis B vaccines
Number of subjects: 150
Study 3429061 — intervention group
Group type: EXPERIMENTAL
Intervention: imidazole salicylate (750 mg t.i.d.)
Number of subjects: 9
Study 3429061 — intervention group
Group type: EXPERIMENTAL
Intervention: indomethacin (50 mg b.i.d. plus placebo)
Number of subjects: 9
Study 30317290 — intervention group
Group type: EXPERIMENTAL
Intervention: 1gm acetaminophen
Number of subjects: 220
Study 30317290 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch)
Number of subjects: 220
Study 28962596 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic treatment individualized to each woman
Number of subjects: 56
Study 28962596 — intervention group
Group type: COMPARATOR
Intervention: Conventional primary health care (Control)
Number of subjects: 56
Study 26314215 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to recorded children's songs with integrated heartbeat sounds (Baby Go To Sleep compact disc) before and during the head CT (Exp group, n=30)
Number of subjects: 62
Study 26314215 — intervention group
Group type: COMPARATOR
Intervention: No music (Con group, n=32)
Number of subjects: 62
Study 23216412 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg b.d.
Number of subjects: 190
Study 23216412 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxoprofen 60 mg t.d.s.
Number of subjects: 190
Study 23216412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 20864893 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg flumazenil
Number of subjects: 24
Study 18710436 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat-based starch hydrolysates, glucose syrups, maltodextrins
Number of subjects: 90
Study 18710436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 17131980 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 weeks of prayer/distant healing from professional healers
Number of subjects: 156
Study 17131980 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 weeks of prayer/distant healing from nurses with no prior training or experience in distant healing
Number of subjects: 156
Study 17131980 — intervention group
Group type: COMPARATOR
Intervention: No distant healing (control group)
Number of subjects: 156
Study 14762500 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% chlorhexidine gel (CHX), n = 15
Number of subjects: 30
Study 14762500 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel, n = 15
Number of subjects: 30
Study 11424245 — intervention group
Group type: EXPERIMENTAL
Intervention: Advantage‐S (spermicide containing nonoxynol‐9)
Number of subjects: 100
Study 11424245 — intervention group
Group type: COMPARATOR
Intervention: Vaginal lubricant (control group)
Number of subjects: 100
Study 11424245 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose N‐9 products
Number of subjects: 100
Study 8796770 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2)
Number of subjects: 206
Study 8796770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 1618247 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% prednicarbate cream
Number of subjects: 24
Study 1618247 — intervention group
Group type: COMPARATOR
Intervention: 0.1% betamethasone-17-valerate cream
Number of subjects: 24
Study 1618247 — intervention group
Group type: COMPARATOR
Intervention: 0.05% clobetasol-17-propionate cream
Number of subjects: 24
Study 1618247 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 24
Study 6377071 — intervention group
Group type: EXPERIMENTAL
Intervention: Early PEEP at 8 cm H2O
Number of subjects: 92
Study 6377071 — intervention group
Group type: COMPARATOR
Intervention: Control (no PEEP)
Number of subjects: 92
Study 30426921 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor residual spraying (IRS)
Number of subjects: 7211
Study 30426921 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide impregnation of bednets
Number of subjects: 7211
Study 30426921 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide wall painting
Number of subjects: 7211
Study 30426921 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever camps
Number of subjects: 7211
Study 30426921 — intervention group
Group type: EXPERIMENTAL
Intervention: Female community health volunteers (FCHVs)
Number of subjects: 7211
Study 30426921 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 7211
Study 28730841 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual coaching sessions, tailored information, and materials for 6 months
Number of subjects: 314
Study 28730841 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 314
Study 26519669 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 DAAs (setrobuvir, danoprevir/r, mericitabine) plus ribavirin for 12 weeks (Group A: G1a)
Number of subjects: 110
Study 26519669 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 DAAs (setrobuvir, danoprevir/r, mericitabine) plus ribavirin for 24 weeks (Group B: G1a)
Number of subjects: 110
Study 26519669 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 DAAs (setrobuvir, danoprevir/r) plus ribavirin for 12 weeks (Group E: G1b)
Number of subjects: 110
Study 26519669 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 DAAs (setrobuvir, danoprevir/r) plus ribavirin for 24 weeks (Group D: G1b)
Number of subjects: 110
Study 24555499 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraurethral 2% lidocaine jelly instilled for 15 minutes (Group C)
Number of subjects: 400
Study 24555499 — intervention group
Group type: COMPARATOR
Intervention: Intraurethral 2% lidocaine jelly instilled for 5 minutes (Group A)
Number of subjects: 400
Study 24555499 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraurethral 2% lidocaine jelly instilled for 20 minutes (Group D)
Number of subjects: 400
Study 24555499 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraurethral 2% lidocaine jelly instilled for 10 minutes (Group B)
Number of subjects: 400
Study 22853822 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia group (HG)
Number of subjects: 26
Study 22853822 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (PG)
Number of subjects: 26
Study 19272659 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental acetylcholine (Ach; 20, 50 and 100 microg/min) infusion
Number of subjects: 52
Study 19272659 — intervention group
Group type: COMPARATOR
Intervention: Control group (103 matched subjects, 64 males, average age 51.3 years) with angiographically normal LAD and BDI <10, HAM-D17 <7
Number of subjects: 52
Study 17008536 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) after inductions 1 and 2
Number of subjects: 317
Study 17008536 — intervention group
Group type: COMPARATOR
Intervention: Control group (no G-CSF)
Number of subjects: 317
Study 17008536 — intervention group
Group type: COMPARATOR
Intervention: Both groups (G-CSF and control)
Number of subjects: 317
Study 15978638 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular low to moderate intensity physical exercise
Number of subjects: 140
Study 15978638 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 140
Study 11923797 — intervention group
Group type: EXPERIMENTAL
Intervention: DUETT vascular hemostasis device
Number of subjects: 630
Study 11923797 — intervention group
Group type: COMPARATOR
Intervention: Standard manual compression
Number of subjects: 630
Study 10457868 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms ethinyl estradiol (EE) + 75 micrograms gestodene (GSD) (Harmonet, Wyeth‐Lederle; n = 15)
Number of subjects: 44
Study 10457868 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms EE + 150 micrograms desogestrel (DSG) (Mercilon, Organon n = 17)
Number of subjects: 44
Study 10457868 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms EE + 150 micrograms DSG (Marvelon, Organon, n = 12)
Number of subjects: 44
Study 7501709 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 electrode placement
Number of subjects: 10
Study 7501709 — intervention group
Group type: COMPARATOR
Intervention: L2 electrode placement
Number of subjects: 10
Study 7501709 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective assessment
Number of subjects: 10
Study 1886348 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 0.5%
Number of subjects: 0
Study 1886348 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 0
Study 31626010 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior tilt ≥20°
Number of subjects: 555
Study 31626010 — intervention group
Group type: COMPARATOR
Intervention: Posterior tilt <20°
Number of subjects: 555
Study 29303810 — intervention group
Group type: EXPERIMENTAL
Intervention: TEP hernia repair with lightweight (Ultrapro) mesh
Number of subjects: 950
Study 29303810 — intervention group
Group type: COMPARATOR
Intervention: TEP hernia repair with heavyweight (Prolene) mesh
Number of subjects: 950
Study 26419871 — intervention group
Group type: EXPERIMENTAL
Intervention: SSGs in combination with cultured autologous epidermal cells (ECs)
Number of subjects: 40
Study 26419871 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with SSGs
Number of subjects: 40
Study 24626433 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg) plus Ezetimibe (10 mg) daily
Number of subjects: 2353
Study 24626433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2353
Study 24626433 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 2353
Study 24626433 — intervention group
Group type: COMPARATOR
Intervention: Placebo (AURORA trial)
Number of subjects: 2353
Study 24626433 — intervention group
Group type: EXPERIMENTAL
Intervention: Any LDL-C-lowering therapy
Number of subjects: 2353
Study 22298168 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical cardioversion in Euthyroid patients (Group 1)
Number of subjects: 67
Study 22298168 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical cardioversion in Hyperthyroid patients (Group 2)
Number of subjects: 67
Study 22298168 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical hyperthyroid patients
Number of subjects: 67
Study 22298168 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical hyperthyroid patients
Number of subjects: 67
Study 22298168 — intervention group
Group type: COMPARATOR
Intervention: Comparison of clinical and subclinical hyperthyroid patients to Euthyroid patients
Number of subjects: 67
Study 19761983 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET imaging with revascularization
Number of subjects: 182
Study 19761983 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 182
Study 19761983 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 182
Study 19761983 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine increase (for a 10-mumol/l increase)
Number of subjects: 182
Study 19761983 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF decrease (for a 2% decrease)
Number of subjects: 182
Study 17209666 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine/enalapril 10mg/10mg once daily
Number of subjects: 0
Study 17209666 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine/enalapril 10mg/20mg once daily
Number of subjects: 0
Study 17209666 — intervention group
Group type: COMPARATOR
Intervention: Lercanidipine/enalapril
Number of subjects: 0
Study 15126816 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral needle ablation (TUNA)
Number of subjects: 121
Study 15126816 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 121
Study 11458142 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 135
Study 11458142 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 135
Study 11458142 — intervention group
Group type: COMPARATOR
Intervention: Control group (lower expectations)
Number of subjects: 135
Study 9721113 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured health visitor management with dietetic, paediatric, and social work input
Number of subjects: 229
Study 9721113 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (Control)
Number of subjects: 229
Study 9721113 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured health visitor management
Number of subjects: 229